543500 logo

Evoq Remedies BSE:543500 Stock Report

Last Price

₹9.18

Market Cap

₹124.8m

7D

-6.3%

1Y

-38.6%

Updated

27 Mar, 2024

Data

Company Financials

Evoq Remedies Limited

BSE:543500 Stock Report

Market Cap: ₹124.8m

543500 Stock Overview

Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India.

543500 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Evoq Remedies Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evoq Remedies
Historical stock prices
Current Share Price₹9.18
52 Week High₹19.44
52 Week Low₹8.90
Beta0
1 Month Change-29.44%
3 Month Change-37.76%
1 Year Change-38.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO-61.35%

Recent News & Updates

Recent updates

Shareholder Returns

543500IN PharmaceuticalsIN Market
7D-6.3%2.7%2.5%
1Y-38.6%63.9%47.3%

Return vs Industry: 543500 underperformed the Indian Pharmaceuticals industry which returned 65% over the past year.

Return vs Market: 543500 underperformed the Indian Market which returned 48.6% over the past year.

Price Volatility

Is 543500's price volatile compared to industry and market?
543500 volatility
543500 Average Weekly Movement11.3%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: 543500's share price has been volatile over the past 3 months.

Volatility Over Time: 543500's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
2010n/an/ahttps://www.evoqremedies.com

Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India. The company trades in sweeteners, such as acesulfame potassium, aspartem, dextrose, erythritol, euro vanillin powder, malodextrin, miglitol, neotame, pharma sugar; amino acids, such as L- alanine, L-arginine, L-aspartic acid, L-carnitine, L-cystine, L-glutamic acids, L-glutamine, L-glutathione, L-glycine, L-isoleucine, L-lavine, L-leucine, L-ornathene, L-aspartate, L-phenylamine, L-serine, L-threonine, L-trytophan, L-tyrosine, L-lysine, N-acetyl, and L-andystine; excipients, which include aspartem, bronopol, cross carmellous sodium, cross povidone, ethyl olliate, hard peraffin, hpmc all grades, light liquid paraffin, mannitol, menthol crystal, etc.; neutraceuticals, such as alpha lipoic acid, astaxanthin, bacopa benfothiamine, betacarotene, biotin, bonistein, bovine colostrum powder, etc.; and opthalamics, which include atropine sulphate, bimatoprost, brimonidine, bromfenac, cyclopentolate, dorzolamide fluoromethelone, flurbiprofen, gatifloxacin, ketorolac tromethamine, latanoprost, loteprednol etabonate, moxifloxacin, natamycin, nepafenac, olopatadine, sulphacetamide sodium, timolol meleate, etc. It also offers ointments, such as adapalene, allantoin, avobenzone, azealic acid beclomethasone di propionate, betamethasone and salts, calamine, chlorocresol, citrimide clindamycin phoshphate, clobetasol propionate, clotrimazole, cyclosporine, fluocinolol acetonide, fusidic acid, gamabenzene, gentamycin sulphate, halobetasol, hydroquinone, etc.; and oncology drugs, such as abiraterone acetate, alfuzosin, anastrazole, axitinib azacitidine, bicalutamide, bleomycin, bosutinib, busualphan cabazitaxel amphorous, capcitabine, carboplatin, cisplatin, etc. In addition, the company offers vitamins, dairy and spice products, sterile, active pharmaceutical ingredients, and veterinary feed products. The company was incorporated in 2010 and is based in Ahmedabad, India.

Evoq Remedies Limited Fundamentals Summary

How do Evoq Remedies's earnings and revenue compare to its market cap?
543500 fundamental statistics
Market cap₹124.85m
Earnings (TTM)₹13.63m
Revenue (TTM)₹145.25m

9.2x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
543500 income statement (TTM)
Revenue₹145.25m
Cost of Revenue₹65.29m
Gross Profit₹79.96m
Other Expenses₹66.33m
Earnings₹13.63m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.00
Gross Margin55.05%
Net Profit Margin9.39%
Debt/Equity Ratio5.1%

How did 543500 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.